SCHEMBL10127252

SCHEMBL10127252

CSc1nc(Nc2ccnc(Cl)c2)c(C(N)=O)c(OC(C)=O)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 2/20 0.37
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
SMARCA2 P51531 3/20 0.36
SMARCA4 P51532 3/20 0.36
SYK P43405 2/20 0.35
MAPK3 P27361 1/20 0.34
PPARG P37231 2/20 0.34
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
PIK3CA P42336 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33
GRM4 Q14833 1/20 0.33
KARS1 Q15046 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127249 0.87 GAA (0.36) ZAP70MAPK3PPARGHTTMAPK10
SCHEMBL10127227 0.85 CA1 (0.40) ZAP70JAK2JAK1SMARCA2SMARCA4
SCHEMBL13070939 0.84 TNF (0.39) ZAP70JAK2JAK1SYKPPARG
SCHEMBL10127179 0.80 SMN1; SMN2 (0.38) PPARGHTTCA1CA2CA7
SCHEMBL10127247 0.79 KMT2A (0.41) JAK2PPARGKMT2A
SCHEMBL10127132 0.79 SYK (0.38) ZAP70SYKPPARGMAPK1HTT
SCHEMBL282425 0.78 TNF (0.42) PPARGGRM4SMN1; SMN2
SCHEMBL10127241 0.78 KIT (0.35) ZAP70SYKMAPK1HTTPIK3CA
SCHEMBL10127194 0.78 GAA (0.37) ZAP70SYKPPARGHTTGAA
SCHEMBL10127243 0.76 ZAP70 (0.33) ZAP70PPARGMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
WO-2010128659-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ZAP70 2470/4885JAK2 1536/4885JAK1 2743/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ZAP70 2470/4885JAK2 1536/4885JAK1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.